ADA Insights: Strategic T1D Screening and Management : Episode 1

Opinion

Video

March 5, 2024

Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Robert Gabbay, MD, PhD, delineates key differences between type 1 and type 2 diabetes, including autoimmune antibodies, insulin resistance, and insulin deficiency.

Now Viewing

EP: 1.Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

EP: 2.Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

EP: 3.Identifying Risk to Enable Early Detection of Type 1 Diabetes

EP: 4.Challenges in Autoantibody Screening for Type 1 Diabetes

EP: 5.Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

EP: 6.Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

EP: 7.Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com

June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Myasthenia gravis diagnosis | Image Credit: Maggie L. Shaw/sora.chatgpt.com

June 19th 2025

RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis

Abigail Lewis

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.

Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.